GlassScriptPhysician profile
Joseph Vitiello
NPI 1932189537
$5,760.82
in general payments reported to CMS, 2019-2025
25 companies · $502 in 2025
The $502 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,566 · 2020: $351 · 2021: $716 · 2022: $589 · 2023: $750 · 2024: $1,287 · 2025: $502.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,539.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,539.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $657.14 | 2019-2025 | Farxiga |
| Boston Scientific Corporation | $647.57 | 2024-2025 | Watchman Flx |
| Novartis Pharmaceuticals Corporation | $603.19 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $601.63 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $599.43 | 2019-2025 | Eliquis, Camzyos |
| Amgen INC. | $532.30 | 2019-2023 | Repatha |
| Pfizer INC. | $515.92 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $358.31 | 2021-2023 | Verquvo |
| Lilly USA, LLC | $216.74 | 2023-2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $174.24 | 2020-2022 | |
| Medtronic, INC. | $119.34 | 2023 | Linq II |
| Irhythm Technologies, INC. | $117.51 | 2019-2022 | |
| Heartflow, INC. | $96.70 | 2024-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $96.14 | 2019 | |
| Alnylam Pharmaceuticals INC. | $83.28 | 2024-2025 | Amvuttra |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $70.59 | 2019 | |
| Sanofi-Aventis U.S. LLC | $56.58 | 2019-2021 | |
| Kiniksa Pharmaceuticals, LTD. | $48.77 | 2023 | Arcalyst |
| Kiniksa Pharmaceuticals International, Plc | $41.48 | 2024 | Arcalyst |
| Atricure, INC. | $25.97 | 2023 | |
| Cook Medical LLC | $23.02 | 2025 | Zenith Alpha |
| Regeneron Healthcare Solutions, INC. | $21.88 | 2019 | |
| Xeris Pharmaceuticals, INC. | $21.30 | 2025 | Gvoke Hypopen |
| Abbott Laboratories | $16.20 | 2023 | Mitraclip |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Vitiello listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.